

Impact the antibiotic resistance for *Staphylococcus aureus* in hospitalized cancer patients in Erbil Governate/Iraq

Abstract

Background: Infection is a continuous problem in cancer patient especially in developing country. Multidrug-resistant *Staphylococcus aureus* are among the most frequent complication in immunocompromised cancer patients and pose the greatest risk to immunocompromised cancer patient.

Objectives: Our study aimed to carry out a study on isolated *Staphylococcus aureus* from various clinical samples among cancer patient in Erbil city and analyze its epidemiology and antibiotics susceptibility pattern test and multi-drug resistance.

Materials and Methods: A total of 865 from 2016 until 2020 were isolated *Staphylococcus aureus* from 6 clinical samples (Urine, Sputum, Wound swab and Nasal swab, Blood, Stool) from patient attending Nanakaly Hospital and from both male and female. Only 100 cases had been identified as isolates *S.aureus* which was identified by using macroscopical, microscopical, biochemical tests and Vitek 2 compact system. Also antibiotic susceptibility test were performed by Vitek 2 compact on 19 antibiotics.

Results: Only 100 *S.aureus* isolates were isolated from 865 samples distribution according to their source of isolation in cancer patient, urinary tract infection is the most our specimen followed by wound infection, respiratory tract infection, blood infection and gastrointestinal infection. Breast cancer is the most common in our study followed by Colon cancer and Multiple myeloma, the percentage of females infected with *S.aureus* more than the males, females being 74/865(8.5%) and males being 28/865(3.2%), after 2016 infections by *S.aureus* was increased in young and middle-aged people being 52/100(52%) in total, from 2016-2020 *S.aureus* infected patients with breast cancer was 47/100(47%), colon was 27/100(27%) and multiple myeloma was 26/100(26%). Although (Aztreoman, Ertapenem, Ticarcillin-clavulanic acid) can be considered as effective agents toward MDR strains for empirical antibiotic therapy in cancer patients. *S.aureus* isolates had resistance to more than six antibiotics.

Conclusions: The study findings showed a significant distribution of MDR *S.aureus* which may increase the burden of healthcare-associated infections in cancer patients. Moreover, mechanisms of resistance should also be investigated for better characterization of multi-drug resistance of *S.aureus* isolates.

Keywords: *S. aureus*, age, gender, cancer patient, multidrug resistant.

Introduction

The relation between bacteria and cancer Tumor growth and metastasis are complicated biological process that involves a subset or individual cancer cells detaching from the primary tumor, migrating to the blood/lymph, and colonizing distant organs or tissues (Zhang et al.,2014).Neutrophils are the first line of defense in the host immune system against pathogen infection and act as a double-edged sword in the processes of cancer occurrence and development (Coffelt et al.,2016).Cancer metastasis is one of the leading causes of cancer related mortality worldwide, and approximately 13% of all tumorrelated deaths are related to metastasis. Currently, surgical treatment is one of the most effective strategies for cancer patients, and most cancer patients receive at least one surgical procedure as part of their treatment (Wyld et al.,2015).Colorectal cancer (CRC) is one of the most common malignancies and among the leading causes of death in the industrialized world (Coffelt et al.,2016).when clinically suspected, diagnostic workup includes cultures and imaging, and treatment includes broad spectrum antibiotics and drainage (Abreu et al.,2011). Lung cancer is the leading cause of cancer-related death in the western hemisphere (Siegel et al.,2014). Nosocomial infections caused by CoNS (Coagulase Negative Staphylococci) are more likely to occur among patients with malignancy especially those who develop chemotherapy-induced damage to mucosal surfaces and neutropenia (Boyce,2004). *S. aureus* is also reported to be the second most common cause of bloodstream infection after coagulase-negative Staphylococcus in patients with neoplastic disease(Wisplinghoff et al.,2003).SABIs (Staphylococcus aureus Bloodstream Infections) in cancer patients are a significant cause of morbidity and mortality in both neutropenic and non-neutropenic patients (González-Barca et al.,2001).Infections triggered by *S. aureus* are a primary source of sickness predominantly among the immunosuppressive cancer patients (Brook and Frizier,1998). In addition, *S. aureus* is a common cause of SSI (Surgical Site Infection) after breast operations. Studies found that *S. aureus* caused 19% and 40%, respectively, of SSIs following breast cancer operations (Omar and Al-Mousa,2013). Gram-positive bacteria account for at least half of all microbiologically documented infections in cancer patients (Mikulska et al.,2014). In addition, *S. aureus* infection mediates the enhancement of non-small cell lung cancer cell metastasis due to up regulation of the TLR4/MyD88 pathway (Toll-like receptor/Myeloid differentiation primary response 88) pathway (An et al.,2016). Although the prevalence of *S. aureus* as a cause of infection in cancer patients varies widely depending on the specific population, the type of infection studied, and geographic location, *S.aureus* has a major clinical impact on patients with malignancy (Bodro et al.,2014).National surveillance reports have shown that *S.aureus* is the second leading cause of CLABSI (Central Line-associated Bloodstream Infection) (Sievert et al.,2013).The mortality rate in

cancer patients with *S. aureus*-CLABSI is 25%–30%, and more than 50% of patients develop hematogenous complications (Ghanem et al.,2007).In this context, bacterial pathogenicity factors may play a decisive role by stimulating cancer cell growth. while a strong proliferative effect has been described for LPS(Lipopolysaccharide), the endotoxin of Gram-negative bacteria, in lung, liver, ovarian, gastric and breast cancer (Wang et al.,2015).

Although the most common pathogens found in NSCLC (Non-small lung cell cancer) are of Gram-negative origin, Gram-positive germs such as *S. aureus* and *Streptococcus pneumoniae* account for about 25% of pulmonary infections in lung cancer patients and are the leading cause of septicemia in lung cancer (Berghmans et al.,2003). Pulmonary bacterial infections are frequently found in advanced stages of lung cancer and may contribute to the progression of this disease (Berghmans et al.,2003). The influenza virus is known to increase the susceptibility to pneumonia caused by *S. aureus*. Furthermore, this latter caused 4% of sepsis among hospitalized patients with cancer (Torres et al.,2015).

Invasive methicillin-susceptible *Staphylococcus aureus* (MSSA) infections should be treated with an anti-staphylococcal beta-lactam such as cefazolin or nafcillin. In a matched case control study in which approximately 40% of patients had cancer, treatment of MSSA bacteremia with vancomycin, as opposed to a betalactam, was associated with higher mortality (Kim et al.,2008). Multidrug-resistant (MDR) *Staphylococcus aureus* is a gram-positive, common pathogen for nosocomial bacteria that induces pneumonia, sepsis, and bacteremia, especially among intensive care unit patients (Jang,2016). The percentage of *S. aureus* isolates among cancer patients that are methicillin-resistant varies geographically but broadly appears to be on the rise (Montassier et al.,2013). Since 2000, multiple cases of hospital and community acquired MRSA prostatic abscess have been reported (Sukhal et al.,2013). *S. aureus* infection has been recognized as one of the most urgent public health threats not only because it is resistant to all commonly used antibiotics (Recker et al.,2017). Vancomycin remains the mainstay of treatment for MRSA; however, high vancomycin failure rates among patients with cancer and MRSA bloodstream infection have been reported (Mahajan et al.,2012). Many strategies have been advocated to prevent MRSA infection with variable degree of evidence based, including search and destroy policy, restrictive antibiotic prescribing policy (Watters et al.,2000).

Methods

Sample collection :A total of (865) samples were collected from cancer patients with 3 main types from hospitalized patient with cancer(Breast cancer, Colon cancer, Multiple myeloma). Six different

2016	40	27	110	73	150	100	
2017	16	8	184	92	200	100	
2018	25	11	200	89	225	100	
2019	12	5	220	95	232	100	
2020	7	12	51	88	58	100	
Total	100	11.5	765	88	865	100	0.0961

Table 1.

Incidence of *Staphylococcus aureus* among genders

In 2016 out of **150** samples the female ratio was more than the males, the males had **8(5.3%)** positive cases and **25(16.6%)** negative cases and for the females we had **32(21 %)** positive cases and **85(57%)** negative cases. In 2017 out of **200** samples the female ratio exceeded the males we had **140(70%)** female samples in which **10(5%)** were positive and **130(65%)** were negative, for the males we had **60(30%)** samples in which **6(3%)** were positive and **54(27%)** negative. As for 2018 and 2019, in 2018 we had **225** samples and 2019 **232** samples, female's ratio exceeding male's, for 2018 females we had **183(81%)** samples **18(8%)** positive, **165(73.3%)** negative and the males had **42(18.6%)** samples **7(3.1%)** were positive and **35(15.5%)** negative, as for 2019 we had **158(68%)** female samples and **76(33.6%)** male ones for the females were **8(3.4%)** positive and **150(64.6%)** negative as for males **10(3.3%)** were positive and **130(43.3%)** negative, In 2020 female had **6(10%)** positive cases and **42(72%)** negative cases and for males we had **1(1.7%)** positive cases and **9(15%)** negative cases. Statistical analysis showed that non- significant correlation between *S.aureus* and gender ($P > 0.05$) as in **Table (2)**.

Table (2): Incidence of *Staphylococcus aureus* among genders.

Year	Male		Female		Total	P value
	P(No%)	N(No%)	P(No%)	N(No%)	No(%)	
2016	8(5.3)	25(16.6)	32(21)	85(57)	150(100)	0.0589
2017	6(3)	54(27)	10(5)	130(65)	200(100)	
2018	7(3.1)	35(15.5)	18(8)	165(73.3)	225(100)	
2019	6(2.6)	70(30)	8(3.4)	150(64.6)	232(100)	
2020	1(1.7)	9(15)	6(10)	42(72)	58(100)	
Total	28(3.2)	193(22)	74(8.5)	572(66)	865(100)	

P=Positive ,N=Negative ,No=Number,%=percentage

Distribution of *Staphylococcus aureus* in different clinical samples

From 2016 until 2020 *S. aureus* were isolated from 6 clinical samples (Urine, Sputum, Wound and Nasal swabs, Blood, Stool) in 2016 urine was the major source of *S.aureus* 24/150 that's 16% and wound swab second 9/150 meaning 6%, sputum and blood were the least of the samples 7/150 meaning 4.6%, we didn't have any stool samples. In 2017 urine 6/200(3%) being the most and wound swab 4/200(2%) being the second, sputum 3/200(1.5%) being third and blood 2/200(1%) and stool 1/200(0.5%). In 2018 urine 10/225(4.4%) being the most, wound swab 5/225(2.22%) being the second most, blood 4/225(1.7%) and stool 4/225 (1.7%), sputum 2/225(0.8%). In 2019 urine also was the major source being 5/232(2.1%) and blood being the second most 4/232(1.7%), wound swabs 2/232(0.9%) stool being the last having 1/300(0.3%) and didn't have any blood samples. In 2020 urine remained the main source being 4/58(7%) and wound swabs 2/58(3.4%) and blood 1/58(1.72%) and didn't have sputum and stool specimens. Statistical analysis showed that significant correlation between *S. aureus* and different clinical samples (P >0.05) as in **Table (3)and Figure (1)**.


Table (3) Distribution of *Staphylococcus aureus* in different clinical samples.

Years		Urine	Sputum	Wound Swab	Blood	Stool	Total	P- value
		N(%)	N(%)	N(%)	N(%)	N(%)	N(%)	
2016	Positive	24(60%)	4(10%)	9(22.5%)	3(7.5%)	-	40(6.4%)	
	Negative	60(54%)	10(9%)	25(22.4%)	15(13%)	-	110(13%)	
2017	Positive	6(37%)	3(18%)	4(25%)	2(12.5%)	1(6.25%)	16(9%)	
	Negative	110(60%)	17(9%)	46(25%)	6(2.3%)	5(2.7%)	184(21%)	
2018	Positive	10(40%)	2(8%)	5(20%)	4(16%)	4(16%)	25(3%)	

2019	Negative	125(62%)	30(15%)	20(10%)	13(6.5%)	12(6%)	200(23%)	
	Positive	5(41%)	-	2(16.6%)	4(33%)	1(8.3%)	12(1%)	
2020	Negative	108(49%)	-	54(24.5%)	43(19.5%)	15(7%)	220(25%)	
	positive	4(57%)	-	2(29%)	1(14.3%)	-	7(0.8%)	
Total	Negative	30(59%)	-	15(29%)	2(4%)	-	51(6%)	
Total		486(57%)	128(15%)	182(21%)	75(8.8%)	38(4.4%)	865	0.0340

N=Number of samples %=Percentage

Figure (1) Distribution of *S.aureus* in different clinical samples



Incidence of Staphylococcus aureus among ages

The incidence of S.aureus in 2016 was seen mostly among young-adults and people younger than 60 years old (19-59) having 24/40(60%), meanwhile in 2017 it was different it was seen mostly among the elderly (60 or older) having 9/16 (56%). In 2018 also it was seen mostly between the ages 19 to 59 providing 13/25(52%) and in 2019 also the majority whom were infected were between 19 and 59 years old having 7/12(58%), lastly in 2020 also mostly between the ages 19 and 59 years having 4/7(57%). Statistical analysis showed that significant correlation between bacteria and age ($P < 0.05$) as in Table (4) **Figure (2)**.

Table (4) The relation between S.aureus and ages.

Years	≤18 No.(%)	19-59 No.(%)	60≤ No.(%)	Total No.(%)	P-value
2016	5(12.5%)	24(60%)	11(27.5%)	40(100%)	
2017	3(18.75%)	4(25%)	9(56.25%)	16(100%)	
2018	7(28%)	13(52%)	5(20%)	25(100%)	
2019	2(16.6%)	7(58%)	3(25%)	12(100%)	
2020	1(14.28%)	4(57%)	2(28.6%)	7(100%)	
Total	18(18%)	52(52%)	30(30%)	100(100%)	<0.0001

No.= number of positive patients %=percentage





Figure (2) The relation between *S.aureus* and ages.

Types of cancer among patients infected with *Staphylococcus aureus*

In 2016 *S.aureus* was present mostly in patients with breast cancer being **22/40(55%)**, multiple myeloma **10/40(25%)** and colon cancer being **8/40(20%)**. In 2017 *S.aureus* was present mostly in patients with multiple myeloma type being **7/16(44%)** breast cancer being second and colon cancer being least. In 2018 out of **25** patients with *S.aureus* **11** were colon cancer being **(44%)** while in breast cancer being **8/25(32%)** and lastly in multiple myeloma being the least having **6/25(24%)**. In 2019 out of **12** patients with *S.aureus* **9** were breast cancer being **(75%)** while in colon cancer being **2(17%)** and lastly in multiple myeloma **1(8%)**. Lastly in 2020 mostly being breast cancer **3/7(43%)**. Multiple myeloma and colon cancer being **2/7(29%)** for each. Statistical analysis showed that significant correlation between types of cancer and *S. aureus* ($P < 0.05$) as in **Table (5)** and **Figure(3)** .

Table (5) Types of cancer among patients infected with infected *S.aureus*

Type	Breast	Colon	Multiple Myeloma	Total	P-value
	No(%)	No(%)	No(%)	No(%)	
2016	22(55%)	8(20%)	10(25%)	40(100)	
2017	5(31%)	4(25%)	7(44%)	16(100)	
2018	8(32%)	11(44%)	6(24%)	25(100)	
2019	9(75%)	2(17%)	1(8%)	12(100)	
2020	3(43%)	2(29%)	2(29%)	7(100)	
Total	47(47%)	27(27%)	26(26%)	100(100)	<0.0001



No: number of patients, %: Percentage

Figure(3) Types of cancer among patients infected with infected *S.aureus*.

Number and percentage of antimicrobials resistance among *Staphylococcus aureus* The antibiotics resistance pattern of (100) isolates of *S.aureus* were screened for their resistance to nineteen widely used antibiotics from 2016 until 2020 , in 2016 the most resistance were to (Tigecycline **31/40(77.5%)**), Piperacillin **30/40(75%)**, Aztreonam **28/40(70%)** and lastly Vancomycin **27/40(67.5%)** and were sensitive to Amikacin **28/40(70%)**, in 2017 most resistance were to Amoxicillin **13/16(81%)** and Aztreonam being **14/16(87%)**) and sensitivity to Ciprofloxacin and Ticarcillin-clavulanic acid being **7/16(43.7%)** . In 2018 the most resistance was to Ciprofloxacin being **19/25(76%)** and the least resistance to Imipenem **9/25(36%)** and in 2019 the most resistance was to Ceftriaxone and Ertapenem **10/12(83%)** and the least resistance to Gentamycin **5/12 (42%)**. In 2020 the most resistance was to Ampicillin, Amoxicillin, Cefepime, Tigecycline and Vancomycin being 6/7(86%) as in **Table (6)**.

Table (3-6) Number and percentage of antimicrobials resistance among *S.aureus*

ANTIBIOTICS	2017 (N=16)			2018 (N=25)			2019 (N=12)			2020(=7)					
	R N(%)	I N(%)	S N(%)	R N(%)	I N(%)	S N(%)	R N(%)	I N(%)	S N(%)	R N(%)	I N(%)	S N(%)			
Ampicillin	26(65%)	4(10%)	10(25%)	11(68%)	1(6.2%)	5(31%)	16(64%)	3(12%)	6(24%)	9(75%)	1(8.3%)	2(16.6%)	6(86%)	-	1(14.3%)
Amoxicillin	21(52.5%)	5(12.5%)	14(34%)	13(81%)	-	3(18.7%)	14(56%)	2(8%)	9(36%)	8(66%)	-	4(33%)	6(86%)	-	1(14.3%)
Amoxiclav	19(47.5%)	3(0.07%)	18(45%)	10(62%)	-	6(37.5%)	15(60%)	1(4%)	9(36%)	9(75%)	-	3(25%)	4(57%)	1(14.3%)	2(28.6%)
Ceftriaxone	15(37.5%)	1(0.02%)	24(60%)	12(75%)	-	4(25%)	13(52%)	4(16%)	8(32%)	10(83%)	-	2(16.6%)	5(71%)	-	2(28.6%)

Aztreonam	28(70%)	1(0.02%)	11(27%)	14(87%)	1(6.2%)	1(6.2%)	17(68%)	2(8%)	6(24%)	7(58%)	2(16.6%)	3(25%)	4(57%)	-	3(43%)
Piperacillin	30(75%)	4(10%)	6(15%)	11(68%)	2(12.5%)	3(18.7%)	12(48%)	3(12%)	10(40%)	8(66%)	1(8.3%)	3(25%)	4(57%)	1(14.3%)	2(28.6%)
Nitrofurantoin	6(15%)	10(25%)	24(60%)	8(50%)	4(25%)	4(25%)	12(48%)	4(16%)	9(36%)	6(50%)	2(16.6%)	4(33%)	3(43%)	2(28.6%)	2(28.6%)
Ertapenem	5(12.5%)	8(20%)	27(67%)	11(68%)	2(12.5%)	3(18.7%)	15(60%)	3(12%)	7(28%)	10(83%)	-	2(16.6%)	4(57%)	-	3(43%)
Amikacin	12(30%)	-	28(70%)	7(43%)	3(18.7%)	6(37.5%)	15(60%)	5(20%)	5(20%)	8(66%)	1(8.3%)	3(25%)	5(71%)	-	2(28.6%)
Gentamycin	10(25%)	7(17.5%)	23(57%)	9(56%)	3(18.7%)	4(25%)	17(68%)	3(12%)	4(16%)	5(42%)	3(25%)	4(33%)	5(71%)	1(14.3%)	1(14.3%)
Levofloxacin	16(40%)	-	24(60%)	10(62%)	2(12.5%)	4(25%)	14(56%)	5(20%)	6(24%)	6(50%)	1(8.3%)	5(41%)	4(57%)	1(14.3%)	2(28.6%)
Cefepime	13(32.5%)	9(22.5%)	18(45%)	6(37%)	5(31%)	5(31%)	13(52%)	5(20%)	6(24%)	9(75%)	-	3(25%)	6(86%)	-	1(14.3%)
Tobramycin	24(60%)	2(0.05%)	14(35%)	12(75%)	1(6.2%)	3(18.7%)	16(64%)	4(16%)	5(20%)	7(58%)	1(8.3%)	4(33%)	5(71%)	-	2(28.6%)
Tigecycline	31(77.5%)	-	9(22%)	9(56%)	3(18.7%)	4(25%)	10(40%)	5(20%)	10(40%)	8(66%)	-	4(33%)	6(86%)	-	1(14.3%)
Imipenem	11(27.5%)	8(20%)	21(52%)	9(56%)	2(12.5%)	5(31%)	9(36%)	3(12%)	13(52%)	7(58%)	-	5(41%)	4(57%)	1(14.3%)	2(28.6%)
Ciprofloxacin	25(62.5%)	6(15%)	9(22%)	8(50%)	1(6.2%)	7(43.7%)	19(76%)	1(4%)	5(20%)	6(50%)	1(8.3%)	5(41%)	5(71%)	-	2(28.6%)
Vancomycin	27(67.5%)	1(0.02%)	12(30%)	10(62%)	2(12.5%)	4(25%)	14(56%)	2(8%)	9(36%)	7(58%)	-	5(41%)	6(86%)	-	1(14.3%)
Doripenem	-	13(32%)	27(67%)	7(43%)	3(18.7%)	6(37.5%)	13(52%)	5(20%)	7(28%)	8(66%)	-	4(33%)	4(57%)	-	3(43%)
Ticarclil-clavulanic acid	-	11(27%)	29(72.5%)	5(31%)	4(25%)	7(43.7%)	11(44%)	4(16%)	10(40%)	9(75%)	-	3(25%)	5(71%)	-	2(28.6%)

R=resistance, I= intermediate , S= sensitive, N=number of patients, %= percentage

MDR among *Staphylococcus aureus* in 2020

In 2020 out of 58 samples 7 were positive and antibiotics susceptibility test was made for the all isolates and the results showed that the bacterium was resistant to the most antibiotics as seen in Table (7) they had resistance to more than three classes and most isolates resistance to more than 6 antibiotics as in table.

Table (7) Percentage of MDR among *S.aureus* in 2020

Antibiotics	No.(percentage)(N total=7)
Ampicillin (10mcg)	6(86%)
Amoxicillin (20mcg)	6(86%)
Amoxiclav (30mcg)	4(57%)
Ceftriaxone (30mcg)	5(71%)
Aztreonam (30mcg)	4(57%)
Piperacillin (100mcg)	4(57%)
Nitrofurantoin (300 mcg)	3(43%)
Ertapenem (10mcg)	4(57%)
Amikacin (10mcg)	5(71%)
Gentamycin(10mcg)	5(71%)
Levofloxacin(10mcg)	4(57%)
Cefepime (30mcg)	6(86%)
Tobramycin (10mcg)	5(71%)
Tigecycline (15mcg)	6(86%)
Imipenem (10 mcg)	4(57%)
Ciprofloxacin(5 mcg)	5(71%)
Vancomycin (30 mcg)	6(86%)
Doripinem (10mcg)	4(57%)
Ticarcillin-clavulanic acid (75mcg)	5(71%)

No.(N)=number of patients

Discussion

Gram-positive bacteria account for at least half of all microbiologically documented infections in cancer patients (Mikulska et al., 2014), *S. aureus* infection incidence may be increasing, at least in some regions (Asgeirsson et al., 2011), probably due to higher numbers of invasive procedures and/or at-risk situations. Due to surgery, long-term stay intravenous catheters, repeated radiotherapy, and chemotherapy, cancer patients that suffer from inhibited bone marrow function, neutropenia, and mucosal barrier damage can be easily infected with Gram-positive bacteria (Holland et al., 2014). A total of (865) samples were collected from six sources (Urine, Wound and Nasal swabs, Sputum, Blood, Stool) from hospitalized patient with cancer (Breast, Colon, Multiple Myeloma) in Nanakali hospital in Erbil city from January 2016 to November 2020. After collection all bacterial isolates were subjected to a series of confirming tests.

From 2016 to 2020 the percentage of female infected with *S. aureus* were more than the males, female being 74/865(8.5%) and males being 28/865(3. 2%) from 2019 to 2020 the percentage of females

infected with *S. aureus* were more than the males, females being 74/865(8.5%) and males being 28/865(3.2%). Our results disagreed with that reported by (Smit et al., 2017) who found that male infected with *Staphylococcus* were more than female a total of 2638 patients infected with *S. aureus* 1022(38.7%) were females and 1616(61.3%) were males in (Northern Denmark).

The incidence of *Staphylococcus aureus* in 2016 was seen mostly among young-adults and people younger than 60 years old (19-59) having 24/40(60%), meanwhile in 2017 it was different it was seen mostly among the elderly (60 or older) having 9/16 (56%). In 2018 also it was seen mostly between the ages 19 to 59 providing 13/25(52%) and in 2019 also the majority whom were infected were between 19 and 59 years old having 7/12(58%), lastly in 2020 also mostly between the ages 19 and 59 years having 4/7(57%). Statistical analysis showed that significant correlation between bacteria and age. From 2016-2019 the total *Staphylococcus aureus* infected patients with breast cancer was 47/100(47%), colon cancer was 27/100(27%), and multiple myeloma was 26/100(26%) this rise in breast cancer is due to the high number of females infected with Breast cancer and colon cancer for males which were more predominant in 2016 than multiple myeloma, our result agrees with the results recorded by (Bai et al., 2018) in which total of 214 cancer patients 40/214(19%) were breast cancer and 23/214(11%) gastric cancer and the least multiple myeloma having 3/214(1.4%), but our result disagrees with the results reported by (Espersen et al., 1987) in which (71%) multiple myeloma and (28%) acute lymphatic leukemia and (4.4) which is endocarditis. In the developing world, cancer is projected to increase by 70% over the next 20–25 years. Breast cancer represents 20–30% of cancer among women and is likely to account for a major part of that increase. These expectations are anticipated because the populations of developing countries are ageing and cancer is largely a disease of older people. Life-style changes are likely to contribute (Majid et al., 2017) In both the Middle-East and the West, carcinoma of the breast is the most common malignancy of women. In the West, there is a cultural tendency toward late marriages and limited childbearing. In this setting, multiparity and breast feeding are protective against breast cancers that are predominantly found after the menopause. In the Middle-East, breast cancer is frequently seen during the childbearing years (Majid et al., 2009)

The extensive emergence of Multidrug-resistant (MDR) bacteria has increased the burden of morbidity and mortality among cancer patients with BSI (Marín et al., 2014). In recent decades, antimicrobial resistance in *S. aureus* isolates has emerged worldwide. Multi-drug resistance in *S. aureus* is defined by the existence of methicillin resistance or lack of susceptibility to greater than or equal to one active agent in greater than or equal to three antimicrobial categories (Magiorakos et al., 2012). In 2020 out of 58 samples 7 were positive and antibiotics susceptibility test was made for the all isolates and the results showed that the bacterium was resistant to the most antibiotics as seen in Table (3-7) they had resistance to more than three classes of antibiotics mostly (86%) of isolates, our finding is higher than study done by (Bai et al., 2018) who recorded that out of 214 isolates (14.5%) were found to be multi-drug resistance and also with study done by (Zhouqi et al., 2021), who recorded that the prevalence of MRSA was (44%) among *S. aureus* bacteremia in cancer patients. Our results showed that the most effective antibiotics were (Nitrofurantoin, Amoxiclav, Aztreonam, piperacillin, Ertapenem, Levofloxacin, Imipenem, Doripinem) showing sensitivity to more than (40%) to these 8 antibiotics as seen in Table (3-7). *S. aureus* is one of the 'ESKAPE' organisms that are responsible for the majority of bacterial infections in patients with malignancy (EJ, 2013). Cancer patients are highly susceptible to blood stream infection (BSI) due to frequent hospital admissions, cytotoxic chemotherapy, use of invasive procedures, and exposure to broad-spectrum antibiotics (Walshe et al., 2002). Accordingly, they witnessed a more significant increase in the incidence of BSI, and a higher mortality rate than noncancer patients in recent years (Hsieh et al., 2019), with prevalence ranging from 11 to 38% and the mortality rate around 40%

(Macedo et al., 2019) .Monitoring cancer occurrence in young adults, often under 50 years, is informative because it often reflects relatively recent changes in exposure to carcinogenic factors. Younger generations worldwide are experiencing an earlier and longer lasting exposure to excess adiposity over their lifetime than previous generations. Numerous cancers are associated with excess bodyweight, and evidence from experimental studies from murine models suggests that obesity and an obesogenic diet accelerate the multistage transition from normal tissue to invasive malignancy and metastatic disease (Sung et al.,2019). So the rise in cancer between ages 18 and 60 maybe due to obesity and smoking.

References

- Zhang Y, Yang P, Wang X-F.** Microenvironmental regulation of cancer metastasis by mirnas. Trends Cell Biol. 2014; 24:153–160.
- Coffelt SB, Wellenstein MD, de Visser KE.** Neutrophils in cancer: neutral no more. Nat Rev Cancer. 2016; 16(7):431-446.
- Wyld L, Audisio RA, Poston GJ.** The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol. 2015;12(2):115-124.
- Abreu D, Arroyo C, Suarez R.** Community-acquired methicillin resistant *Staphylococcus aureus*: a new aetiological agent of prostatic abscess. British Medical Journal. 2011.
- Siegel R, Ma J, Zou Z, Jemal A.** Cancer statistics. CA Cancer J Clin. 2014; 64:9–29.
- Boyce JM.** Coagulase Negative Staphylococci. In: CG Mayhall, editor. Hospital epidemiology and infection control. Philadelphia, PA: LWW. 2004; 495– 516.
- Wisplinghoff H, Seifert H, Wenzel RP, Edmond.** Current trend in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in a hospital in the United States. Clin Infect Dis .2003; 36; 1103-1110.
- González-Barca E, Carratalà J, Mykietiuk A, Fernández-Sevilla A , Gudiol F.** Predisposing Factors and Outcome of *Staphylococcus aureus* Bacteremia in Neutropenic Patients with Cancer.Eur J Clin Microbiol Infect Dis. 2001; 20:117–119.
- Brook I, Frazier EH.** Aerobic and anaerobic infection associated with malignancy. Support Care Cancer. 1998; (6):125-131.
- Omar AA, Al-Mousa HH.** Surgical site infection complicating breast cancer surgery in Kuwait. ISRN Prev Med. 2013; 2013:295783.

Mikulska M, Viscoli C, Orasch C. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. *J Infect* .2014; 68:321–31.

An J, Li Z, Dong Y. Methicillin-resistant *Staphylococcus aureus* infection exacerbates NSCLC cell metastasis by upregulating TLR4/MyD88 pathway. *Cell Mol Biol*. 2016; 62(8):1-7.

Bodro M, Gudiol C, Garcia-Vidal C. Epidemiology, antibiotic therapy and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in cancer patients. *Support Care Cancer*. 2014; 22:603–10.

Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A. Antimicrobial- resistant pathogens associated with healthcare- associated infections: summary of data reported to the national healthcare safety network at the centers for disease control and prevention, 2009– 2010. *Infect Control Hosp Epidemiol*. 2013; 34:1–14.

Ghanem GA, Boktour M, Warneke C, Pham-Williams T, Kassis C, Bahna P. Catheter- related *Staphylococcus aureus* bacteremia in cancer patients: high rate of complications with therapeutic implications. *Medicine (Baltimore)*. 2007; 86:54–60.

Wang Y, Tu Q, Yan W, Xiao D, Zeng Z, Ouyang Y, Huang L, Cai J, Zeng X, Chen YJ, Liu

A. CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-κB and MAPK pathway. *Biochem Biophys Res Commun*. 2015; 456:373–379.

Behera D, Myneedu VP, Verma AK and Sharma PP. A pilot study of same day sputum smear examination, its feasibility and usefulness in diagnosis of pulmonary TB. *Indian J Tuberc*.2011; 58(4):160-167.

Torres VB, Azevedo LC, Silva UV. Sepsis-associated outcomes in critically ill patients with malignancies. *Ann Am Thorac Soc*. 2015; 12(8):1185–1192.

Kim SH, Kim KH and Kim HB. Outcome of vancomycin treatment in patients with methicillin-susceptible *Staphylococcus aureus* bacteremia. *Antimicrob Agents Chemother* .2008; 52:192–7.

Jang S. Multidrug efflux pumps in *Staphylococcus aureus* and their clinical implications. *J Microbiol*. 2016; 54(1):1-8.

Montassier E, Batard E, Gastinne T, Potel G, de La Cochetiere MF. Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance. *Eur J Clin Microbiol Infect Dis*. 2013; 32:841–50.

Sukhal S, Zamora J, and Herrera P. An unusual cause of prostatic abscess: a case report and review of literature,” *Infectious Disease in Clinical Practice*. 2013;21(5);289-291.

Recker M, Laabei M, Toleman MS. Clonal differences in *Staphylococcus aureus* bacteraemia-associated mortality. *Nat Microbiol.* 2017;2(10):1381-1388.

Mahajan SN, Shah JN, Hachem R . Characteristics and outcomes of methicillin-resistant *Staphylococcus aureus* bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center. *Oncologist .*2012; 17:1329–36.

Watters GWR, Patel SG, Rhys-Evans PH. Partial laryngectomy for recurrent laryngeal carcinoma. *Clin Oto laryngol.* 2000; 25:146–152.

Nakasone I, Kinjo T, Yamane N, Kisanuki K and Shiohira CM. Laboratory- based evaluation of the colorimetric VITEK 2 Compact System for species identification and of the Advanced Expert System for detection of antimicrobial resistances: VITEK 2 Compact System identification and antimicrobial susceptibility testing. *Diagnosis Microbiology Infection Disease Journal.*2007; 58:191-198.

Kaase M, Baars B, Friedrich S, Szabados F and Gatermann SG. Performance of Micro ScanWalk Away and Vitek 2 for detection of oxacillin resistance in a set of methicillin-resistant *Staphylococcus aureus* isolates with diverse genetic Backgrounds. *Journal of Clinical Microbiology.* 2009; 47(8):2623-2625.

Mikulska M, Viscoli C, Orasch C. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. *J Infect .*2014; 68:321–31.

Asgeirsson H, Gudlaugsson O, Kristinsson KG, Heiddal S, Kristjansson M. *S. aureus* bacteraemia in Iceland, 1995-2008: changing incidence and mortality. *Clin Microbiol Infect.* 2011; 17:513-518.

Holland T, Fowler VG Jr, Shelburne SA. 3rd. Invasive gram-positive bacterial infection in cancer patients. *Clin Infect Dis* 2014; 59 (5): S331-4.

Smit J, López-Cortés LE, Kaasch AJ, Søgaard M, Thomsen RW, Schönheyder HC, Rodríguez-Baño J, Nielsen H. Gender differences in the outcome of community- acquired *Staphylococcus aureus* bacteraemia: a historical population-based cohort study. *Clin Microbiol Infect.* 2017; 23(27-32).

Bai C, Li D, Zhang Q, Zheng S, Li Z, Wang Z, Li Z, Zhang W. Prognostic analysis of cancer patients with *Staphylococcus aureus* infection: five-year experience at a comprehensive cancer centerd. *Int J Clin Exp Med.* 2018; 11(8):8640-8645.

Espersen F, Frimodt-Møller N, Rosdahl, Jessen O, Faber VK. Rosendal *Staphylococcus aureus* bacteremia in patients with hematological malignancies and/or agranulocytosis, National library of Medicine.1987; 222(5):465-70.

Majid R, Mohammed H, Saeed H, Safar B, Hughsun MD. Breast cancer in Iraq is associated with a unimodally distributed predominance of luminal type B over luminal type A surrogates from young to old age. *BMC Women's Health.* 2017; 17(27):1-8.

Majid R, Mohammed H, Saeed H, Safar B, Hughsun MD. Breast cancer in kurdish women of northern Iraq: incidence, clinical stage, and case control analysis of parity and family risk. *BMC Women's Health*. 2009; 9(33):1-6.

Marín M, Gudiol C, Ardanuy C, García-Vidal C, Calvo M, Arnan M. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours. *J Infect*. 2014; 69:417–23.

Magiorakos AP, Srinivasan A, Carey RB. Multidrug-resistant, extensively drug-resistant and pandrug resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* .2012; 18:268-81.

Bai C, Li D, Zhang Q, Zheng S, Li Z, Wang Z, Li Z, Zhang W. Prognostic analysis of cancer patients with *Staphylococcus aureus* infection: five-year experience at a comprehensive cancer centerd. *Int J Clin Exp Med*. 2018; 11(8):8640-8645.

Zhouqi Li, Zhuang H, Wang G, Wang H and Dong Y. Prevalence, predictors, and mortality of bloodstream infections due to methicillin- resistant *Staphylococcus aureus* in patients with malignancy: systemic review and meta-analysis .*BMC infectious Diseases*.2021; 21:74.

Bow EJ. There should be no ESKAPE for febrile neutropenic cancer patients: the dearth of effective antibacterial drugs threatens anticancer efficacy, *J Antimicrob Chemother*. 2013; 68(3): 492–5.

Walshe LJ, Malak SF, Eagan J, Sepkowitz KA. Complication rates among Cancer patients with peripherally inserted central catheters. *J Clin Oncol*. 2002; 20(15):3276–81.

Hsieh RW, Schrank GM, Hsu WT, Su KY, Lee CC. Temporal trend of microbiological profiles among patients with bloodstream infections: A comparison between cancer and noncancer patients in a nationwide database. *J Clin Oncol*. 2019;37.

Macedo F, Monteiro AR, Soares R, Pereira T, Bonito N, Sousa G. Bacteremia in oncologic patients and multi drug resistant microorganisms: A growing issue. *Support Care Cancer*. 2019; 27(1):S139.

Sung H, Siegel R, Rosenberg P, Jernal A. Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. *Lancet Public Health*. 2019; 4: e137–47.

UNDER PEER REVIEW